Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated the immunogenicity and safety of a booster dose of Pneumo 23 in children aged 12 to 18 months who were primed with Prevnar; the report c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumo 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar (pneumococcal conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Streptococcus Pneumoniae | Phase 3 | Status: COMPLETED